Market ExpansionFormycon has secured a new commercial partner, Horus Pharma, to market FYB203 in selected European countries, which could enhance its market penetration.
Regulatory ApprovalFYB203 has received approval from both the European Commission and the FDA, indicating strong regulatory support for the product.
Strategic PartnershipsKlinge Biopharma GmbH entered an exclusive license agreement for the commercialization of Eylea biosimilar FYB203 in the U.S. and Canada, expanding Formycon's commercial partnerships.